Jasper Therapeutics, Inc. — Form 8-K/A

On July 16, 2026, Jasper Therapeutics acquired Kira Pharmaceuticals in an all-stock merger. Kira's equity holders received 5.195M Jasper common shares and 4.645M non-voting convertible preferred shares (convertible at 61:1 ratio). Concurrently, Jasper raised $132M via private placement of non-voting convertible preferred stock. Kira had accumulated deficit of $180.8M and substantial going-concern doubt as of Dec 31, 2025; it was unprofitable since inception with $2.4M operating loss in 2025. Post-merger, Jasper agreed to seek stockholder vote within 120 days to convert preferred stock to common; if not approved within 12 months, holders can require repurchase at fair market value.